Sunday 18 October 2026
Export AFIB’s income statement to Excel — free account
Acutus Medical, Inc.
AFIB Healthcare Medical Devices
In the quarter to December 2024, revenue grew 204.2%, EPS grew 95.9% and free cash flow grew 76.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow AFIB
| Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 4 | 6 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
0.09 | 0.85 | 13.06 | 5.66 | 38.83 | 4.73 | 4.73 | — |
Altman Z-Score |
(28.51) | (15.48) | (3.18) | (4.35) | (0.35) | — | — | — |
Altman Z″-Score (non-manufacturers) |
(66.67) | (34.40) | (4.43) | (7.73) | (2.87) | (9.12) | (31.23) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
(0.44) | (0.34) | (2.35) | (4.33) | (13.62) | (1.11) | (1.11) | — |
Beneish M-Score |
(2.49) | — | — | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.53 | 0.92 | 2.60 | 0.00 | 0.00 | — |
Price to Tangible BV |
0.00 | 0.00 | 0.54 | 1.10 | 3.02 | 0.00 | 0.00 | — |
EV/Sales |
1.01 | 1.56 | (0.62) | 2.18 | 28.05 | 7.20 | 7.20 | — |
EV/EBITDA |
10.86 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(0.64) | (0.18) | 0.02 | (0.38) | (2.79) | (0.42) | (0.42) | — |
EV/FCF |
(0.64) | (0.18) | 0.02 | (0.34) | (2.46) | (0.38) | (0.38) | — |
Quick Ratio |
1.76 | 2.15 | 4.74 | 5.65 | 6.09 | 2.26 | 0.73 | — |
Current Ratio |
2.06 | 2.44 | 5.93 | 6.82 | 6.91 | 2.58 | 0.88 | — |
Net Debt/EBITDA |
9.90 | (0.43) | (0.75) | 0.59 | 1.06 | 0.63 | (0.25) | — |
Debt/Assets |
113.69% | 63.97% | 26.04% | 24.04% | 20.75% | 37.06% | 99.68% | 0.00% |
Debt/Equity |
(2.81) | (39.27) | 0.46 | 0.39 | 0.32 | 1.42 | (1.92) | — |
Asset Turnover |
0.49 | 0.08 | 0.02 | 0.10 | 0.06 | 0.04 | 0.17 | — |
Operating CF/Net income |
3.32 | 0.77 | 2.24 | 0.85 | 0.84 | 0.58 | 0.71 | — |
Capex/Depreciation |
(0.06) | (12.88) | (0.02) | (1.04) | (2.18) | (0.65) | (0.38) | — |
Interest Coverage |
(0.01) | (2.07) | 7.97 | (19.75) | (16.59) | (3.26) | (7.22) | — |
| 153.11% | (220.29%) | (43.84%) | (101.32%) | 205.55% | 54.27% | 26.79% | — | |
| (23.11%) | (87.15%) | (26.13%) | (64.96%) | (68.45%) | (147.70%) | (369.25%) | — | |
ROIC |
(0.51%) | (174.27%) | 76.43% | (153.63%) | (161.69%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(69.91%) | (290.25%) | (39.75%) | (96.90%) | (71.90%) | (176.52%) | (4,795.50%) | — |
Average Days of Receivables |
142.65 | 578.43 | 2,157.85 | 76.81 | 93.15 | 33.85 | 27.64 | — |
Research and Development Expense of Revenue |
0.00% | 48.60% | 102.87% | 212.49% | 395.25% | 812.02% | 880.75% | — |
Selling, General and Administrative Expense of Revenue |
51.77% | 196.34% | 670.24% | 367.97% | 594.96% | 946.65% | 615.42% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.10 | 0.09 | 0.15 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
2.28% | 42.32% | 112.17% | 79.67% | 142.99% | 105.57% | 95.61% | — |
Graham Net Nets |
(8.21) | (1.41) | 1.50 | 0.64 | 0.26 | (1.52) | (1.52) | — |
Graham Number |
1.69 | 1.38 | 0.00 | 0.00 | 0.00 | 1,044.88 | 0.00 | — |
Earnings Yield |
(545.33%) | (1,335.95%) | (104.32%) | (120.82%) | (211.93%) | (507.09%) | (507.09%) | — |
Free Cash Flow Yield |
(1,778.87%) | (1,036.62%) | (225.26%) | (112.22%) | (29.33%) | (399.86%) | (399.86%) | — |
Revenue per Share |
0.68 | 0.25 | 0.11 | 0.60 | 0.74 | 4.22 | 3.97 | — |
Operating CF per Share |
(1.06) | (2.17) | (3.12) | (3.48) | (7.47) | (83.31) | (61.89) | — |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.35) | (0.98) | (19.93) | (3.73) | — |
Free Cash Flow per Share |
(1.07) | (2.18) | (3.13) | (3.83) | (8.45) | (103.25) | (65.62) | — |
Cash per Share |
0.47 | 1.01 | 2.68 | 3.52 | 11.50 | 107.07 | 32.79 | — |
Shareholders Equity per Share |
(0.39) | (0.03) | 2.63 | 3.69 | 11.10 | 40.99 | (24.74) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(0.39) | (0.03) | 2.63 | 3.69 | 11.10 | 40.99 | (24.74) | — |
Free Cash Flow |
(31.77) | (63.34) | (89.14) | (109.65) | (96.39) | (69.38) | (35.82) | — |
Working Capital |
13.14 | 27.31 | 98.00 | 107.78 | 129.48 | 50.55 | (2.92) | — |
Capital Expenditures |
(0.11) | (0.22) | (0.23) | (9.97) | (11.22) | (13.39) | (2.04) | — |
Net Current Asset Value |
(14.66) | (8.59) | 59.45 | 62.22 | 85.44 | 4.55 | (17.51) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.01 | 0.03 | 0.08 | 0.58 | 1.33 | 4.72 | 0.94 | — |
Price to Operating Income |
0.00 | 0.00 | 0.96 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
3.73 | 0.02 | 8.42 | 0.70 | 0.42 | 4.65 | 1.36 | — |
Cash ROIC |
(90.79%) | (100.42%) | (47.93%) | (44.31%) | (32.37%) | (50.07%) | (118.39%) | — |
Accounts Receivable Turnover |
2.10 | 0.49 | 0.28 | 5.96 | 6.99 | 13.28 | 10.15 | — |
Accounts Payable Turnover |
9.48 | 3.94 | 0.99 | 4.17 | 2.62 | 3.37 | 2.74 | — |
Inventory Turnover |
6.31 | 3.39 | 0.54 | 2.24 | 1.49 | 1.62 | 1.31 | — |
Average Days of Payables |
24.33 | 97.83 | 182.68 | 83.35 | 189.89 | 153.30 | 77.62 | — |
Days of Inventory on Hand |
34.13 | 151.58 | 132.53 | 181.90 | 297.67 | 332.66 | 145.95 | — |
Average Receivables |
9.62 | 14.64 | 10.78 | 2.90 | 1.21 | 0.21 | 0.21 | — |
Average Payables |
2.02 | 2.62 | 5.00 | 7.89 | 6.07 | 2.74 | 2.74 | — |
Average Inventory |
3.03 | 3.04 | 9.10 | 14.68 | 10.69 | 5.71 | 5.71 | — |
Average Assets |
41.30 | 93.70 | 151.62 | 181.16 | 149.00 | 65.70 | 12.97 | — |
Average Common Equity |
(6.24) | 37.07 | 90.37 | 116.15 | (49.61) | (178.82) | (178.82) | — |
Columns are period end dates